The Potential of Community Pharmacists in NCD Risk Assessment

Non-communicable diseases (NCDs) such as cardiovascular disease, type 2 diabetes and obesity develop over time, often before symptoms become obvious. This makes early risk assessment essential. Community pharmacists are well placed to support that work because they are accessible, familiar health professionals who see people regularly for prescriptions, advice and preventive services. Learn more about リウマチ性疾患の骨関節感染症の診断と治療.

The 2023 APEC Conference on Promoting Community-based Non-Communicable Diseases Integrated Care Model highlighted the value of coordinated, community-level care, particularly for ageing populations. Its focus on prevention, chronic disease management and hybrid participation provides a useful setting for examining how pharmacies can contribute to practical, connected NCD services in Australia.

A Trusted Access Point For Early Detection

Community pharmacies are often easier to reach than a general practice appointment. Many operate in local shopping centres, suburban strips and regional towns, with extended hours and no appointment requirement. For an older person collecting medicines, a parent managing family health or a worker who cannot take time off during business hours, that regular contact can create a valuable opportunity to identify risk.

A pharmacist may notice repeated requests for medicines associated with high blood pressure, elevated cholesterol or glucose management. A brief conversation can uncover missed doses, smoking, low physical activity, poor sleep, alcohol intake or difficulty accessing healthy food. These discussions should be respectful and practical, with attention to a person’s circumstances rather than relying on a checklist alone.

Risk assessment can include blood pressure measurement, waist circumference, body mass index, medication review and, where appropriately trained and equipped, blood glucose or lipid testing. These results do not replace a GP diagnosis. Their value lies in identifying a reason for further assessment and helping people understand why follow-up matters.

Australia’s population is ageing, and many people live with several conditions at once. A person taking medicines for hypertension may also have kidney disease, arthritis or a history of cardiovascular events. A pharmacist who considers the whole medication profile can identify interactions, adherence barriers and warning signs that might otherwise remain disconnected across different appointments.

Building A More Complete Cardiovascular Risk Picture

Cardiovascular risk assessment is most effective when several factors are considered together. A single blood pressure reading may be useful, but it cannot describe a person’s full risk. Pharmacists can help collect a broader picture, including age, family history, smoking status, diabetes history, physical activity, weight trends and current medicines.

The consultation also provides a chance to explain numbers in plain language. Terms such as systolic pressure, LDL cholesterol and absolute cardiovascular risk can be confusing. A pharmacist can connect them to everyday decisions, such as taking medicines consistently, reducing highly processed foods, becoming more active or arranging a medical review. Clear explanations may improve confidence and reduce the tendency to stop treatment when symptoms are absent.

Clinical boundaries remain important. Pharmacists should use validated tools and approved protocols, document findings and refer people with concerning results to a GP or urgent care service. A high reading, chest pain, severe breathlessness, sudden weakness or other acute symptom requires timely medical attention rather than routine pharmacy follow-up.

The Australian healthcare system offers opportunities for this model through collaboration between pharmacies, general practices, pathology providers and allied health professionals. Services funded or supported through Medicare, state programs or pharmacy-based initiatives need clear referral pathways so that a screening result leads to action. Without that connection, assessment can become an isolated measurement rather than part of integrated care.

Supporting Diabetes And Obesity Prevention

Type 2 diabetes often develops alongside excess weight, high blood pressure and reduced physical activity. Community pharmacists can help identify people who may benefit from formal testing or lifestyle support, particularly when they collect repeat prescriptions for conditions linked to metabolic risk. Their regular contact can make prevention a continuing conversation instead of a single campaign during a health-awareness week.

A useful pharmacy consultation should avoid blame. Weight is shaped by income, housing, work patterns, stress, culture, medicines and access to fresh food. In some parts of Australia, especially remote areas, healthy choices can be more expensive or less available than packaged alternatives. A pharmacist can acknowledge these realities and refer people to a GP, dietitian, diabetes educator or community program suited to their location.

Medication review is another important contribution. Some medicines can affect appetite, weight or glucose control, while treatment changes may create new risks. Pharmacists can explain administration, identify side effects and encourage appropriate monitoring. They should not recommend abrupt changes to prescribed treatment, but they can help a patient prepare informed questions for the prescriber.

For Aboriginal and Torres Strait Islander communities, culturally safe care is essential. Risk assessment should respect local leadership, community-controlled health services and the person’s preferred way of discussing health. Partnerships with Aboriginal Community Controlled Health Organisations can make pharmacy-based screening more relevant, trusted and connected to ongoing care rather than treating it as a stand-alone transaction.

Reaching Regional And Remote Communities

Distance is a major factor in NCD prevention and follow-up across Australia. People in the Northern Territory, Western Australia, Queensland and other remote regions may travel long distances for specialist appointments or have limited access to regular general practice services. A local pharmacist may be one of the few consistent health professionals available in the community.

Pharmacy-led risk assessment can help identify people who need a review before their condition becomes urgent. It can also support monitoring between appointments, particularly when pharmacists communicate results securely with a GP, nurse or Aboriginal health service. This approach works best when responsibilities are defined and the patient knows who will provide the next step.

Digital care can extend the model, but technology must suit local conditions. Internet reliability, device access, digital confidence and privacy are practical considerations. The discussion of rural NCD follow-up shows how telemedicine can complement local services when it is designed around continuity, clinical escalation and the realities of rural care.

Pharmacists can also support remote follow-up through medication synchronisation, reminders and communication with visiting clinicians. These measures may reduce missed reviews and unnecessary travel. They should be built around patient consent and secure information sharing, with alternative arrangements for people who cannot use video consultations or online portals.

Turning Screening Into Integrated Care

The strongest case for community pharmacists is not based on isolated testing. It rests on their ability to connect prevention, medication management, education and referral. A person identified as having elevated cardiovascular risk should receive a clear explanation, written information where useful and a practical pathway to confirm the result and begin care.

Workforce training will determine the quality of these services. Pharmacists need skills in measurement technique, motivational communication, cultural safety, privacy, health literacy and escalation. Pharmacy assistants can support administrative tasks and appointment flow, while pharmacists retain responsibility for clinical assessment and referral decisions.

Shared records and consistent documentation are equally important. If a patient’s result is recorded only in a pharmacy system, the broader care team may never see it. Interoperable digital records, agreed referral templates and timely feedback can reduce duplication and help clinicians understand what has already been discussed. Australian privacy requirements must remain central to every stage.

The APEC conference materials provide a useful resource for considering these models across different health systems. The conference resources include information about the program, speakers and downloadable materials, supporting continued discussion about community-based prevention and integrated chronic disease care.

Evaluation should measure meaningful outcomes rather than the number of tests completed. Relevant indicators include confirmed diagnoses, completed referrals, blood pressure control, medication adherence, patient understanding and engagement among underserved groups. Research into chronic disease presentations should also remind clinicians that unusual symptoms and complex conditions require careful medical assessment; related rheumatic disease guidance illustrates why pharmacists must recognise the limits of screening and refer appropriately.

Community pharmacists can become a practical bridge between everyday contact and long-term NCD care. Their contribution is strongest when supported by clinical governance, fair remuneration, reliable referral networks and culturally responsive partnerships. With those foundations, pharmacy-based risk assessment can help Australians act earlier, understand their health risks and stay connected to care.

Health services, pharmacy organisations and community partners can use the APEC event materials to examine how a locally adapted model might work in their setting. Investing in training, shared systems and clear referral pathways will help turn routine pharmacy encounters into timely prevention opportunities for people living with diabetes risk, obesity, cardiovascular risk and other chronic conditions.